DS
ALXN

DRW Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

DRW Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,110
Closed -$204K – 397
2021
Q2 		$204K Buy
+1,110
New +$191K 0.01% 283
2020
Q1 		– Sell
-3,108
Closed -$336K – 398
2019
Q4 		$336K Buy
+3,108
New +$332K 0.01% 158
2018
Q1 		– Sell
-3,120
Closed -$373K – 509
2017
Q4 		$373K Buy
3,120
+420
+16% +$51.1K 0.04% 270
2017
Q3 		$379K Buy
2,700
+900
+50% +$122K 0.12% 34
2017
Q2 		$219K Buy
+1,800
New +$209K 0.04% 56
2014
Q3 		– Sell
-32,503
Closed -$5.08M – 146
2014
Q2 		$5.08M Buy
+32,503
New +$5.13M 0.93% 17

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

DRW Securities's ALXN Position: Q3 2021 in Review

DRW Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,110 shares — an estimated $204K sold.

DRW Securities first reported a position in ALXN in Q2 2014 and held it in 6 quarters. The position peaked at $5.08M in Q2 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • DRW Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • DRW Securities sold 1,110 Alexion Pharmaceuticals shares in Q3 2021, an estimated $204K.
  • DRW Securities first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 6 quarters.
  • DRW Securities's Alexion Pharmaceuticals position peaked at $5.08M in Q2 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on DRW Securities's 13F filing for Q3 2021, filed 12 Nov 2021.